San Diego-based Viking Therapeutics marked itself as a significant competitor during the weight loss drug sector in February soon after revealing promising information from a mid-stage trial of experimental drug VK2735, which prompt it rivaled—and outperformed—Novo and Lilly drugs when given as being a weekly injection As well as in March the c